Silexion Therapeutics Corp - Ordinary Shares (SLXN) analyst actions
Rating and price-target actions on SLXN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SLXN overview →
2 measured SLXN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center | Press release | -0.02% | -22.70% | |
| Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center | Press release | -0.56% | -8.18% |
Keep exploring
More SLXN: earnings → · SEC filings → · SLXN overview →